Go Pro
→ Elon’s AI Phone is coming (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
C$10.09
-1.9%		C$9.76
C$5.66
▼
C$10.37
C$991.16M-0.29093596,353 shs80,185 shs
NVLN
Novelion Therapeutics Inc,
C$0.00
C$10.68
▼
C$16.35
C$251.80MN/A3,220 shs3,639 shs
AXS Cannabis ETF stock logo
THCX
AXS Cannabis ETF
$16.60
$16.60
$14.90
▼
$25.40
$141.07M1.7115,071 shsN/A
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
-1.94%+0.80%+4.45%+7.68%+67.05%
NVLN
Novelion Therapeutics Inc,
0.00%0.00%0.00%0.00%0.00%
AXS Cannabis ETF stock logo
THCX
AXS Cannabis ETF
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
C$10.09
-1.9%		C$9.76
C$5.66
▼
C$10.37
C$991.16M-0.29093596,353 shs80,185 shs
NVLN
Novelion Therapeutics Inc,
C$0.00
C$10.68
▼
C$16.35
C$251.80MN/A3,220 shs3,639 shs
AXS Cannabis ETF stock logo
THCX
AXS Cannabis ETF
$16.60
$16.60
$14.90
▼
$25.40
$141.07M1.7115,071 shsN/A
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
-1.94%+0.80%+4.45%+7.68%+67.05%
NVLN
Novelion Therapeutics Inc,
0.00%0.00%0.00%0.00%0.00%
AXS Cannabis ETF stock logo
THCX
AXS Cannabis ETF
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
3.00
BuyC$9.50-5.85% Downside
NVLN
Novelion Therapeutics Inc,
0.00
N/AN/AN/A
AXS Cannabis ETF stock logo
THCX
AXS Cannabis ETF
1.97
Reduce$16.60N/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
C$547.31M1.81C$2.62 per share3.85C$8.13 per share1.24
NVLN
Novelion Therapeutics Inc,
N/AN/AN/AN/AN/AN/A
AXS Cannabis ETF stock logo
THCX
AXS Cannabis ETF
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
-C$30.73MC$0.1567.27N/A2.72%1.91%0.51%N/A
NVLN
Novelion Therapeutics Inc,
N/AN/AN/AN/AN/AN/AN/AN/AN/A
AXS Cannabis ETF stock logo
THCX
AXS Cannabis ETF
N/AN/AN/AN/AN/AN/AN/AN/AN/A

Latest NVLN, GUD, and THCX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
N/A-C$0.03N/A-C$0.03N/AC$143.97 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
N/AN/AN/AN/AN/A
NVLN
Novelion Therapeutics Inc,
N/AN/AN/AN/AN/A
AXS Cannabis ETF stock logo
THCX
AXS Cannabis ETF
$0.724.34%N/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
4.29
2.28
1.79
NVLN
Novelion Therapeutics Inc,
N/AN/AN/A
AXS Cannabis ETF stock logo
THCX
AXS Cannabis ETF
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
22.71%
NVLN
Novelion Therapeutics Inc,
N/A
AXS Cannabis ETF stock logo
THCX
AXS Cannabis ETF
N/A

Insider Ownership

CompanyInsider Ownership
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
45.62%
NVLN
Novelion Therapeutics Inc,
N/A
AXS Cannabis ETF stock logo
THCX
AXS Cannabis ETF
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
83098.23 millionN/ANot Optionable
NVLN
Novelion Therapeutics Inc,
10918.93 millionN/ANot Optionable
AXS Cannabis ETF stock logo
THCX
AXS Cannabis ETF
N/A8.50 millionN/ANot Optionable

Recent News About These Companies

'Let's Go All In On Cannabis' Grown Rogue's Obie Strickler & Josh Rosen
September 8, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4944073-lets-go-all-in-on-cannabis-grown-rogues-obie-strickler-and-josh-rosen
The Cannabis M&A Wave Is Here. Curaleaf Proved It.
August 23, 2026  |  fool.comhttps://www.fool.com/investing/2026/08/23/the-cannabis-ma-wave-is-here-curaleaf-proved-it-he/
Christina Lake Cannabis Announces Non-Binding Letter of Intent
August 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/21/3348993/0/en/christina-lake-cannabis-announces-non-binding-letter-of-intent.html
NewLake Capital: Discounted Cannabis REIT Offers Inflation-Beating Yields And Rich Upsides
August 18, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4937629-newlake-capital-discounted-cannabis-reit-offers-inflation-beating-yields-and-rich-upsides
Village Farms Is Undervalued As International Cannabis Revenue Hits Record Levels
August 11, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4934930-village-farms-is-undervalued-as-international-cannabis-revenue-hits-record-levels
Trulieve Cannabis: First NYSE-Listed Cannabis Stock Is A Buy
August 9, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4933918-trulieve-cannabis-q2-first-nyse-listed-cannabis-stock-is-a-buy
Trulieve Cannabis Corp. (TRLV) Q2 2026 Earnings Call Transcript
August 7, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4933186-trulieve-cannabis-corp-trlv-q2-2026-earnings-call-transcript
Innovative Industrial Properties: Cannabis Rescheduling Progress Reinforces The Re-Rating Thesis
June 30, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4918995-innovative-industrial-properties-stock-cannabis-rescheduling-progress-reinforces-re-rating-thesis
Cannabis Bioscience International Holdings Opens New Revenue Pathway with First VitaCookies Licensing Agreement
June 22, 2026  |  newsfilecorp.comN
Aurora Cannabis: Weak Near-Term Outlook But Too Cheap To Ignore - Buy
June 12, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4914450-aurora-cannabis-weak-near-term-outlook-but-too-cheap-to-ignore-buy
Herbal Dispatch Completes 452kg Multi Client Medical Cannabis Export Shipment To Europe
June 9, 2026  |  newsfilecorp.comN
Herbal Dispatch Completes Export of 261kg of Medical Cannabis to Europe
May 21, 2026  |  newsfilecorp.comN
Herbal Dispatch Completes Company Record 500kg Medical Cannabis Export Shipment to Europe
May 19, 2026  |  newsfilecorp.comN
Aurora Granted Plant Breeders' Rights, Strengthening Leadership in Cannabis Science
May 14, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/aurora-granted-plant-breeders-rights-strengthening-leadership-in-cannabis-science-302771046.html
Village Farms: U.S. Cannabis Optionality (Rating Upgrade)
May 13, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4903661-village-farms-stock-us-cannabis-optionality
Green Thumb Industries Will Benefit From Medical Cannabis Rescheduling
May 12, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4902943-green-thumb-industries-stock-will-benefit-from-medical-cannabis-rescheduling
Innovative Industrial Properties: Medical Cannabis Rescheduling Implies Bottoming Tenant Default Risks - Reiterate Buy
May 6, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4899092-innovative-industrial-properties-q1-medical-cannabis-rescheduling-implies-bottoming-tenant-risks
Herbal Dispatch Launches Next-Generation E-Commerce Platform, Targeting High-Growth $245 Million Insured Medical Cannabis Segment
May 5, 2026  |  newsfilecorp.comN
Glow Lifetech Expands Distribution with Two of Canada's Largest Cannabis Retailers, Launches New Product Innovation and Advances National Growth Strategy
April 30, 2026  |  newsfilecorp.comN
Cannabis ETFs: Regulatory Momentum Returns Focus
April 30, 2026  |  etftrends.comE

Media Sentiment Over Time

Knight Therapeutics stock logo

Knight Therapeutics TSE:GUD

C$10.09 -0.20 (-1.94%)
As of 09/23/2026 04:00 PM Eastern

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.knighttx.com or www.sedarplus.ca.

Novelion Therapeutics Inc, TSE:NVLN

Novelion Therapeutics Inc, formerly QLT Inc., is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development. The Company holds a portfolio of products through its subsidiary, Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. The Company's portfolio of products include MYALEPT and JUXTAPID. The Company is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.

AXS Cannabis ETF stock logo

AXS Cannabis ETF NYSEARCA:THCX

$16.60 0.00 (0.00%)
As of 03/1/2024

The Cannabis ETF (THCX) is an exchange-traded fund that is based on the AXS Cannabis index. The fund tracks an index of legal cannabis companies selected and weighted by market capitalization. The fund primarily holds North American companies but may also invest in other countries. THCX was launched on Jul 9, 2019 and is managed by AXS Investments.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas